Patients with recurrent, platinum-sensitive epithelial ovarian cancer (defined as disease relapse ≥6 months after first-line platinum-based chemotherapy) typically receive additional platinum-based regimens with or without bevacizumab, although most patients will have further relapse events. Now, data from one of the arms of the phase Ib FORWARD II trial show that the addition of the antibody–drug conjugate mirvetuximab soravtansine to carboplatin and bevacizumab has promising activity in patients with folate-receptor-α-positive (FRα⁺) disease.

A total of 41 women received triplet therapy. FRα positivity was defined as a score of ≥2 + in ≥50% of tumour cells as determined with the VENTANA FOLR1 RxDx immunohistochemistry assay; 49% and 51% of patients had FRα tumour expression levels ≥75% and 50–74%, respectively. Objective response rate (ORR) and safety were the co-primary end points.

复发性铂类敏感上皮性卵巢癌患者（定义为一线铂类化疗后≥6个月疾病复发）通常接受额外的铂类治疗方案，联合或不联合贝伐珠单抗，尽管大多数患者会出现进一步的复发事件。现在，来自 Ib 期 FORWARD II 试验之一的数据表明，在卡铂和贝伐单抗中添加抗体药物缀合物 mirvetuximab soravtansine 对于叶酸受体 α 阳性 (FRα + ) 疾病患者具有良好的^活性。

共有 41 名女性接受了三联疗法。 FRα 阳性定义为使用 VENTANA FOLR1 RxDx 免疫组织化学测定法测定的 ≥50% 肿瘤细胞得分≥2+； 49% 和 51% 的患者 FRα 肿瘤表达水平分别≥75% 和 50-74%。客观缓解率（ORR）和安全性是共同主要终点。